BIOCARTIS GROUP
BE · esercizio 2022 · chiuso il 2022-12-31 · importi in EUR · tutte le identità verificate
Tutti i bilanci di BIOCARTIS GROUP — altri esercizi: 20232021
Chi è
Testo dell'emittente, citato dal deposito senza modifiche né traduzione. ESEF non contiene una classificazione settoriale: quello che segue è quanto la società dichiara di sé nelle informazioni di identificazione previste dallo IAS 1.138.
| Attività e operazioniifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities · lingua dichiarata en · dal deposito del 2023-12-31 | Notes to the consolidated financial statements General information GENERAL 4Up until the date of the Security Enforcement, Biocartis Group NV, a company incorporated in Belgium with registered address at Generaal de Wittelaan 11 B, 2800 Mechelen, Belgium (the ‘Company’) controlled operating subsidiaries that commercialized a proprietary molecular diagnostics (‘MDx’) platform. The Company had established subsidiaries in Belgium (Biocartis NV), the United States of America (Biocartis Inc.) and Italy (Biocartis SRL) as well as a joint venture in Hong Kong (China) (Wondfo-Cartis Ltd.). Since the date of the Security Enforcement, Biocartis NV, Biocartis Inc. and Biocartis SRL ceased to be subsidiaries of the Company. For sake of clarity, any reference in this document to the ‘Group’ shall, as of the date of the Security Enforcement, not be deemed to include Biocartis NV, Biocartis Inc. and Biocartis Italy SRL. The consolidated financial statements have been authorized for issue on 30 December 2024 by the board of directors of the Company (the ‘Board of Directors’). |
| Sede principale dell'attivitàifrs-full:PrincipalPlaceOfBusiness · lingua dichiarata en · dal deposito del 2023-12-31 | Notes to the consolidated financial statements General information GENERAL 4Up until the date of the Security Enforcement, Biocartis Group NV, a company incorporated in Belgium with registered address at Generaal de Wittelaan 11 B, 2800 Mechelen, Belgium (the ‘Company’) controlled operating subsidiaries that commercialized a proprietary molecular diagnostics (‘MDx’) platform. The Company had established subsidiaries in Belgium (Biocartis NV), the United States of America (Biocartis Inc.) and Italy (Biocartis SRL) as well as a joint venture in Hong Kong (China) (Wondfo-Cartis Ltd.). Since the date of the Security Enforcement, Biocartis NV, Biocartis Inc. and Biocartis SRL ceased to be subsidiaries of the Company. For sake of clarity, any reference in this document to the ‘Group’ shall, as of the date of the Security Enforcement, not be deemed to include Biocartis NV, Biocartis Inc. and Biocartis Italy SRL. The consolidated financial statements have been authorized for issue on 30 December 2024 by the board of directors of the Company (the ‘Board of Directors’). |
| Domicilioifrs-full:DomicileOfEntity · lingua dichiarata en · dal deposito del 2023-12-31 | Notes to the consolidated financial statements General information GENERAL 4Up until the date of the Security Enforcement, Biocartis Group NV, a company incorporated in Belgium with registered address at Generaal de Wittelaan 11 B, 2800 Mechelen, Belgium (the ‘Company’) controlled operating subsidiaries that commercialized a proprietary molecular diagnostics (‘MDx’) platform. The Company had established subsidiaries in Belgium (Biocartis NV), the United States of America (Biocartis Inc.) and Italy (Biocartis SRL) as well as a joint venture in Hong Kong (China) (Wondfo-Cartis Ltd.). Since the date of the Security Enforcement, Biocartis NV, Biocartis Inc. and Biocartis SRL ceased to be subsidiaries of the Company. For sake of clarity, any reference in this document to the ‘Group’ shall, as of the date of the Security Enforcement, not be deemed to include Biocartis NV, Biocartis Inc. and Biocartis Italy SRL. The consolidated financial statements have been authorized for issue on 30 December 2024 by the board of directors of the Company (the ‘Board of Directors’). |
| Paese di costituzioneifrs-full:CountryOfIncorporation · lingua dichiarata en · dal deposito del 2023-12-31 | Notes to the consolidated financial statements General information GENERAL 4Up until the date of the Security Enforcement, Biocartis Group NV, a company incorporated in Belgium with registered address at Generaal de Wittelaan 11 B, 2800 Mechelen, Belgium (the ‘Company’) controlled operating subsidiaries that commercialized a proprietary molecular diagnostics (‘MDx’) platform. The Company had established subsidiaries in Belgium (Biocartis NV), the United States of America (Biocartis Inc.) and Italy (Biocartis SRL) as well as a joint venture in Hong Kong (China) (Wondfo-Cartis Ltd.). Since the date of the Security Enforcement, Biocartis NV, Biocartis Inc. and Biocartis SRL ceased to be subsidiaries of the Company. For sake of clarity, any reference in this document to the ‘Group’ shall, as of the date of the Security Enforcement, not be deemed to include Biocartis NV, Biocartis Inc. and Biocartis Italy SRL. The consolidated financial statements have been authorized for issue on 30 December 2024 by the board of directors of the Company (the ‘Board of Directors’). |
| Forma giuridicaifrs-full:LegalFormOfEntity · lingua dichiarata en · dal deposito del 2023-12-31 | Notes to the consolidated financial statements General information GENERAL 4Up until the date of the Security Enforcement, Biocartis Group NV, a company incorporated in Belgium with registered address at Generaal de Wittelaan 11 B, 2800 Mechelen, Belgium (the ‘Company’) controlled operating subsidiaries that commercialized a proprietary molecular diagnostics (‘MDx’) platform. The Company had established subsidiaries in Belgium (Biocartis NV), the United States of America (Biocartis Inc.) and Italy (Biocartis SRL) as well as a joint venture in Hong Kong (China) (Wondfo-Cartis Ltd.). Since the date of the Security Enforcement, Biocartis NV, Biocartis Inc. and Biocartis SRL ceased to be subsidiaries of the Company. For sake of clarity, any reference in this document to the ‘Group’ shall, as of the date of the Security Enforcement, not be deemed to include Biocartis NV, Biocartis Inc. and Biocartis Italy SRL. The consolidated financial statements have been authorized for issue on 30 December 2024 by the board of directors of the Company (the ‘Board of Directors’). |
| Capogruppo ultimaifrs-full:NameOfUltimateParentOfGroup · lingua dichiarata en · dal deposito del 2023-12-31 | Notes to the consolidated financial statements General information GENERAL 4Up until the date of the Security Enforcement, Biocartis Group NV, a company incorporated in Belgium with registered address at Generaal de Wittelaan 11 B, 2800 Mechelen, Belgium (the ‘Company’) controlled operating subsidiaries that commercialized a proprietary molecular diagnostics (‘MDx’) platform. The Company had established subsidiaries in Belgium (Biocartis NV), the United States of America (Biocartis Inc.) and Italy (Biocartis SRL) as well as a joint venture in Hong Kong (China) (Wondfo-Cartis Ltd.). Since the date of the Security Enforcement, Biocartis NV, Biocartis Inc. and Biocartis SRL ceased to be subsidiaries of the Company. For sake of clarity, any reference in this document to the ‘Group’ shall, as of the date of the Security Enforcement, not be deemed to include Biocartis NV, Biocartis Inc. and Biocartis Italy SRL. The consolidated financial statements have been authorized for issue on 30 December 2024 by the board of directors of the Company (the ‘Board of Directors’). |
| Controllanteifrs-full:NameOfParentEntity · lingua dichiarata en · dal deposito del 2023-12-31 | Notes to the consolidated financial statements General information GENERAL 4Up until the date of the Security Enforcement, Biocartis Group NV, a company incorporated in Belgium with registered address at Generaal de Wittelaan 11 B, 2800 Mechelen, Belgium (the ‘Company’) controlled operating subsidiaries that commercialized a proprietary molecular diagnostics (‘MDx’) platform. The Company had established subsidiaries in Belgium (Biocartis NV), the United States of America (Biocartis Inc.) and Italy (Biocartis SRL) as well as a joint venture in Hong Kong (China) (Wondfo-Cartis Ltd.). Since the date of the Security Enforcement, Biocartis NV, Biocartis Inc. and Biocartis SRL ceased to be subsidiaries of the Company. For sake of clarity, any reference in this document to the ‘Group’ shall, as of the date of the Security Enforcement, not be deemed to include Biocartis NV, Biocartis Inc. and Biocartis Italy SRL. The consolidated financial statements have been authorized for issue on 30 December 2024 by the board of directors of the Company (the ‘Board of Directors’). |
Stato patrimoniale
| Voce canonica | EUR |
|---|---|
| Attività non correnti ifrs-full:NoncurrentAssets | 47 354 000 |
| Attività correnti ifrs-full:CurrentAssets | 95 126 000 |
| Totale attivo ifrs-full:Assets | 142 480 000 |
| Patrimonio netto del gruppo ifrs-full:EquityAttributableToOwnersOfParent | -33 897 000 |
| Patrimonio netto ifrs-full:Equity | -33 897 000 |
| Passività non correnti ifrs-full:NoncurrentLiabilities | 142 672 000 |
| Passività correnti ifrs-full:CurrentLiabilities | 33 705 000 |
| Totale patrimonio e passivo ifrs-full:EquityAndLiabilities | 142 480 000 |
Conto economico
| Voce canonica | EUR |
|---|---|
| Ricavi ifrs-full:Revenue | 57 481 000 |
| Costo del venduto ifrs-full:CostOfSales | 29 799 000 |
| Risultato operativo ifrs-full:ProfitLossFromOperatingActivities | -47 047 000 |
| Risultato ante imposte ifrs-full:ProfitLossBeforeTax | -65 621 000 |
| Imposte ifrs-full:IncomeTaxExpenseContinuingOperations | -240 000 |
| Risultato netto ifrs-full:ProfitLoss | -65 381 000 |
| di cui gruppo ifrs-full:ProfitLossAttributableToOwnersOfParent | -65 381 000 |
Verifiche contabili
Ogni prospetto è controllato contro le identità che lo definiscono. Il risultato è mostrato qui che sia positivo o negativo.
| Identità | Esito |
|---|---|
| attivo = correnti + non correnti | verificata |
| attivo = totale patrimonio e passivo dichiarato | verificata |
| risultato netto = ante imposte − imposte | verificata |
Provenienza
Ogni riga porta sotto l'etichetta il concetto della tassonomia IFRS da cui il valore è
stato preso, così com'è nel deposito originale. Il deposito è identificato da
549300J4HOJL5KG8HY54-2022-12-31-ESEF-BE-0.
Apri la relazione depositata — il documento originale su filings.xbrl.org, da cui ogni numero di questa pagina è stato letto.